AstraZeneca has lifted the veil on the large-scale THALES trial of its antiplatelet drug Brilinta in stroke, the company’s last big hope for recouping its substantial investment in the medicine.

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...

The goal of this product is to reduce the severity of perioperative bleeding in patients on ticagrelor (Brilinta®, AstraZeneca) who are undergoing coronary artery bypass graft (CABG) surgery.

AstraZeneca’s new cardiovascular asset comes ... and chronic kidney disease) and Brilinta (approved for coronary acute syndromes). The company says the CSPC drug has potential uses in a range ...

Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...

St James's Place is growing faster than the industry after jumping through regulatory hoops – and the share ...

CytoSorbents (CTSO) announced the U.S. Food and Drug Administration, FDA, has accepted its De Novo medical device application for DrugSorb-ATR ...

US FDA ASSIGNS NEW PDUFA DATE FOR BRILINTA (TICAGRELOR TABLETS) AstraZeneca announced today that the US Food and Drug Administration (FDA) has acknowledged receipt of the company's reply to the ...

Dakota Wealth Management cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.8% in the 3rd quarter, ...

AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 37,100 shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...